
Collaborators investigate novel T-cell receptor therapy
Elicera Therapeutics has entered a Material Transfer Agreement (MTA) with a prominent US cancer centre to evaluate the enhancing effect of the iTANK-technology in a novel T-cell receptor therapy targeting skin cancer and lung cancer. Elicera Therapeutics will make parts of its technology iTANK available to… Read More

